Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 8/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.42 |
| ▸ | GUSB | P08236 | 2/20 | 0.41 |
| ▸ | EBP | Q15125 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | DRD5 | P21918 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | SOD3 | P08294 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292674 | 0.98 | GNAO1 (0.45) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL3109275 | 0.95 | GLB1 (0.40) | GNAO1GNAI3GNAI1EBPSIGMAR1 | |
| SCHEMBL294048 | 0.87 | DRD3 (0.34) | EBPSIGMAR1DRD1DRD4DRD5 | |
| SCHEMBL294119 | 0.86 | GNAO1 (0.41) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL2702582 | 0.85 | GNAO1 (0.43) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL4759046 | 0.82 | GNAO1 (0.38) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL3099250 | 0.81 | EBP (0.47) | GNAO1GNAI3GNAI1GUSBEBP | |
| SCHEMBL25118371 | 0.81 | BCHE (0.43) | GUSBBCHE | |
| SCHEMBL293917 | 0.81 | GLB1 (0.38) | GNAO1GNAI3GNAI1BCHE | |
| SCHEMBL16508848 | 0.81 | GBA1 (0.42) | GNAO1GNAI3GNAI1GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2204394-B1 | PROCESS FOR PRODUCTION OF POLYESTER-CONTAINING FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION FOR USE IN THE PROCESS | TOSOH CORP (JP) | 2017-07-12 | — | — | EP | disclosed |
| US-8980965-B2 | Method for producing polyester type flexible polyurethane foam, and catalyst composition to be used therefor | TOSOH CORPORATION (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20100256249-A1 | METHOD FOR PRODUCING POLYESTER TYPE FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION TO BE USED THEREFOR | TOSOH CORPORATION (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2204394-A1 | PROCESS FOR PRODUCTION OF POLYESTER-CONTAINING FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION FOR USE IN THE PROCESS | Tosoh Corporation (JP) | 2010-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256249-A1 | METHOD FOR PRODUCING POLYESTER TYPE FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION TO BE USED THEREFOR | OR51E2, CYP4F11, FFAR3 | GNAO1 2915/4885GNAI3 3947/4885GNAI1 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.